Welcome to our dedicated page for Zoetis SEC filings (Ticker: ZTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Zoetis Inc. filings document the animal health company's operating results, capital returns, financing activity and governance disclosures. Recent 8-K reports furnish quarterly and annual financial results, guidance, dividend declarations, investor presentations and other Regulation FD disclosures.
The company's proxy materials address board and compensation matters, including executive pay and equity-award disclosures. Other filings record its New York Stock Exchange-listed common stock and debt financing, including a private offering of convertible senior notes, related indenture terms and capped call transactions.
Zoetis Inc. announced that its Board of Directors declared a cash dividend of $0.53 per share for the third quarter of 2026. The dividend will be paid on September 1, 2026 to shareholders of record as of the close of business on July 20, 2026. This reflects ongoing cash returns to common stockholders through regular dividend payments.
Zoetis Inc. director Frank A. D'Amelio bought shares of the company in the open market. He purchased 6,650 shares of Zoetis common stock at a price of $75.39 per share in a single transaction. Following this purchase, he directly owns 21,458 shares of Zoetis common stock.
Zoetis Inc. director Paul Bisaro reported an open-market buy of Common Stock. On May 13, 2026, he purchased 2,000 shares at $75.875 per share in a single transaction. Following this purchase, his direct holdings increased to 27,862 shares of Zoetis common stock.
Zoetis Inc. director Michael B. McCallister reported an open-market purchase of 3,000 shares of Zoetis common stock. The shares were bought indirectly through a family trust at a weighted average price of $77.7578 per share, with individual trade prices ranging from $77.72 to $77.80.
After this purchase, one trust associated with McCallister holds 24,524 Zoetis shares indirectly, while separate records show 1,209 shares held directly and additional shares held through another trust for his spouse and family.
Zoetis Inc. delivered stable first‑quarter 2026 results with modest top-line growth and flat profit. Revenue rose to $2,262 million from $2,198 million, a 3% increase that reflects a 4% foreign-exchange tailwind and a 1% decline on an operational basis.
Net income was essentially unchanged at $601 million, but diluted earnings per share increased to $1.42 from $1.34, helped by a lower share count after substantial buybacks. The company generated $401 million in cash from operations, down from $515 million, while investing $606 million in share repurchases and paying $224 million in cash dividends.
Zoetis ended the quarter with $1,941 million in cash and cash equivalents and $9,045 million in long-term debt, including $2,000 million of 0.250% convertible senior notes due 2029. Management highlighted a lower effective tax rate of 20.7% and continued use of non-GAAP metrics such as adjusted net income of $646 million to evaluate underlying performance.
Zoetis Inc. reported first quarter 2026 revenue of $2.262 billion, up 3% from a year earlier, with organic operational revenue flat. Net income was $601 million, or $1.42 per diluted share, with earnings per share up 6% on a reported basis.
Adjusted net income was $646 million and adjusted diluted EPS was $1.53, up 2% and 9% respectively, and 1% on an organic operational basis. U.S. revenue fell 8% to $1.09 billion amid weaker companion animal demand and greater competition, while International revenue rose 17% to $1.149 billion with strong livestock growth.
Zoetis updated 2026 guidance to revenue of $9.680–$9.960 billion, adjusted net income of $2.870–$2.950 billion and adjusted diluted EPS of $6.85–$7.00, implying low- to mid-single-digit organic operational growth. Management highlighted a robust innovation pipeline and the planned acquisition of Neogen’s animal genomics business in the second half of 2026.
Zoetis Inc. Executive Vice President Kevin Esch reported routine equity compensation activity. On April 30, 2026, he exercised restricted stock units to acquire 259 shares of Zoetis common stock at an exercise price of $0.00 per share. To cover tax obligations, 75 shares of common stock were disposed of at $114.97 per share as a tax-withholding transaction, not an open-market sale. Following these transactions, he directly holds 578 shares of common stock and indirectly holds 124.4082 common stock equivalents in the Zoetis Savings Plan, a 401(k) plan. He also continues to hold RSUs covering 44.1900, 205.8853 and 4043.3874 underlying shares of Zoetis common stock that will vest in stages on specified future anniversaries, subject to continued service.
Zoetis Inc ownership filing shows Vanguard Capital Management beneficially owned 30,277,753 shares of common stock, representing 7.17% of the class as reported with an as-of date of 03/31/2026. The filing states Vanguard exercises sole dispositive power over all 30,277,753 shares and sole voting power over 4,204,907 shares. The filing lists affiliated Vanguard entities that may exercise voting or dispositive power on certain holdings and is signed by Vanguard's Head of Global Fund Administration.
Zoetis Inc ownership update: Vanguard Portfolio Management reports beneficial ownership of 24,070,531 shares of Zoetis common stock, representing 5.7% of the class as of 03/31/2026. The filing states Vanguard exercises sole dispositive power over these shares and reports limited sole voting power of 103,131 shares. The filing notes these holdings include securities held for Vanguard funds and managed clients and identifies Vanguard Portfolio Management LLC and affiliated business divisions as the reporting entities.
FULLER JULIE reported acquisition or exercise transactions in this Form 4 filing.
Zoetis Inc. Executive Vice President Julie Fuller received a grant of 550.6435 phantom stock units on Zoetis common stock at a reference price of $39.64 per unit. Following this award, she holds a total of 1,798.0366 phantom stock units.
Each phantom stock unit represents a fraction of a phantom share of Zoetis common stock plus a small amount of cash-equivalent investments, which typically account for around 5% of the unit’s total value. The units are settled in cash after her separation from service and may be transferred into an alternative investment fund, subject to Zoetis’ limits on the timing, frequency and permissibility of such transfers.